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proteolytic activity of HTRA1, modulating the availability 
of molecules that can change cell growth and differentiation. 
MIF is therefore the first endogenous inhibitor ever found 
for HTRA1. It was found that both molecules were present 
in astrocytes and that the functional binding has the ability 
to modulate astrocytic activities important in development 
and disease of the CNS.
Keywords MIF · HTRA1 · Protein interaction · Yeast-2-
hybrid
Introduction
Macrophage migration inhibitory factor, MIF, is a highly 
conserved 12.5-kDa cytokine-like protein that exhibits a 
unique combination of hormone-, cytokine-, and enzyme-
like properties. It operates via intra- and extracellular pro-
tein–protein interactions as well as via CD74/CXCR2/
CXCR4/CXCR7 receptor-mediated pathways regulating 
immune and inflammatory responses, cell growth, migra-
tion and apoptosis [1–7]. MIF was originally studied in the 
immune system where its expression is high, but MIF is, 
in fact, expressed in many different tissues and cells [8]. In 
the endocrine system, for example in the healthy pancreas, 
MIF is secreted together with insulin. Here MIF acts as an 
autocrine factor to stimulate insulin release [9]. It also binds 
to insulin and promotes its stability [10]. During develop-
ment of the central nervous system (CNS), MIF acts as 
a neurotrophic growth factor and is involved in stem cell 
proliferation and neurogenesis as well as inner ear devel-
opment [4–6, 11, 12]. Deletion of MIF in the mouse CNS 
results in increased anxiety and depression-like behaviors, 
as well as impaired hippocampus-dependent memory, likely 
connected to its influence on stem cells [4]. MIF mediates 
Abstract Macrophage migration inhibitory factor (MIF), 
a small conserved protein, is abundant in the immune- and 
central nervous system (CNS). MIF has several receptors 
and binding partners that can modulate its action on a cel-
lular level. It is upregulated in neurodegenerative diseases 
and cancer although its function is far from clear. Here, we 
report the finding of a new binding partner to MIF, the ser-
ine protease HTRA1. This enzyme cleaves several growth 
factors, extracellular matrix molecules and is implicated in 
some of the same diseases as MIF. We show that the func-
tion of the binding between MIF and HTRA1 is to inhibit the 
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antidepressant actions in voluntary exercise and has the 
ability to increase serotonin secretion in the brain [13]. 
Increased MIF levels also have neuroprotective properties 
and are implicated in wound healing after spinal cord injury 
and peripheral nerve regeneration [14, 15].
An upregulation of MIF has been reported to be detri-
mental in several neurodegenerative diseases such as Alzhei-
mer’s disease (AD), mild cognitive impairment, Parkinson´s 
disease and multiple sclerosis (MS) [16–20]. In AD, MIF 
has been isolated in association with the β-amyloid peptide, 
the main constituent of AD plaques and in vitro, β-amyloid 
induced toxicity could be reversed by the small molecule 
inhibitor of MIF; ISO-1 [21, 22]. These data together with 
the fact that CD74, a common receptor for MIF, is upregu-
lated in neurofibrillary tangles in AD, suggest that MIF may 
be involved in the degenerative process [23].
Recent clinical studies have identified MIF as a marker 
of clinical worsening in MS patients [22, 24, 25]. It inhibits 
the action of glucocorticoids that are used as a treatment to 
shorten MS relapses [26]. MIF also promotes disease pro-
gression in an animal model of MS, experimental autoim-
mune encephalomyelitis (EAE) likely through its ability to 
skew the CNS inflammatory milieu [27]. It has been shown 
that MS patients have a higher expression of the MIF recep-
tor CD74 on monocytes, which may make this cell type 
more reactive, increasing the activity in signaling pathways 
necessary for MAPK activation and cell motility [28, 29].
While the role of MIF in the immune system has been 
thoroughly studied, less is known about its function in the 
nervous system. To further investigate the role of MIF in the 
CNS, we screened a brain cDNA library for new binding 
partners to MIF and identified the serine protease HTRA1 
as an MIF interacting protein.
HTRA1 is a highly conserved 51-kDa protein [30, 31]. It 
is expressed in several tissues including the brain, where it 
is present in most cells [32–36] The majority of the HTRA1 
is secreted into the extracellular space while the remain-
ing fraction localizes to the cytoplasm attached to microtu-
bules [37, 38]. In the extracellular space, HTRA1 acts as an 
enzyme that digests a number of proteins and extracellular 
matrix molecules [39–43]. Intracellularly, it is also been 
implicated as a tumor suppressor and in cell proliferation 
and migration [35, 36, 40, 43, 44]. HTRA1 has been sug-
gested to play a role in several diseases such as macular 
degeneration, arthritis and CARASIL [39, 45–49]. In Alz-
heimer’s disease HTRA1 has been implicated in the disas-
sembly and degradation of tau and Aβ fibrils [50].
The function of the interaction was first investigated 
biochemically and then studied in vitro in astrocytes that 
express both MIF and HTRA1. In these two systems, the 
enzymatic activity of HTRA1 was inhibited by MIF, and 
consequently HTRA1-mediated degradation of growth fac-
tors was also blocked.
Methods
Full-length human MIF and the two truncated forms 
were PCR amplified from MGC clone 61527 (IMAGE: 
6047427, Source BioScience). The PCR fragments were 
purified and cloned, directly in-frame with the Gal4 DNA-
BD, by In-Fusion technique (Clontech, #639690) into the 
pGBKT7 vector (Clontech) pre-opened with restriction 
enzymes EcoRI (Invitrogen, #15202-013) and BamHI 
(Invitrogen, #15201-023). The construct was transformed 
into TOP10 bacteria (Invitrogen) and grown at 37 °C ON. 
Colonies were selected, analyzed and sequenced using a 
T7 primer.
Transformation of competent yeast cells with plasmid 
DNA
The Yeastmaker Yeast Transformation System 2 (Clon-
tech, PT1172-1) was used in all transformations. Com-
petent Y2HGold or Y187 cells (Clontech) were prepared 
and the vectors introduced into the yeast cells using an 
adapted lithium acetate (LiAc)/single-stranded DNA/
polyethylene glycerol (PEG) method (Clontech). Dena-
tured carrier DNA (50 µg, Clontech #630440) and 100 ng 
vector DNA was added to 50 μL competent yeast cells 
together with 500 μL PEG/LiAC. After 30 min incubation 
at 30 °C, 20 µL DMSO was added and the cells were heat-
shocked at 42 °C for 15 min. The cells were spun down at 
high speed for 15 s, 1 mL YPD plus medium (Clontech) 
was added and the cells were incubated with shaking at 
125 rpm at 30 °C for 30 min. After incubation, the cells 
were centrifuged at 115g for 5 min and resuspended in 
1 mL 0.9% NaCl. The cell suspension was spread onto 
selective agar plates and grown at 30 °C for 3–5 days.
Yeast two‑hybrid screenings
The Matchmaker Gold Yeast Two-Hybrid (Y2H) sys-
tem (Clontech, #630489) was used in accordance with 
manufacturer’s protocol to identify proteins interacting 
with MIF. A pre-transformed human fetal brain cDNA 
library (Clontech, #630469) in Y187 cells was used for 
the screen. The Y187 cells were mated with the haploid 
MATα reporter strain, Y2HGold, expressing MIF. Prior 
to all screenings, every construct was tested for auto-
activation, toxicity and protein expression according to 
the manufacture’s protocol. Positive protein-interacting 
colonies were re-streaked several times before isolating 
colonies for analysis. Vector DNA was isolated from the 
selected colonies and interacting proteins identified by 
DNA sequencing.
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Co‑transformation
Interacting proteins retrieved from Y2H screenings were 
verified by co-transformation experiments. Coding regions 
of interacting proteins were expressed in pGADT7 and trans-
formed into Y2HGold expressing pGBKT MIF. Co-trans-
formed Y2HGold were grown on selective agar plates for 
3–5 days at 30 °C according to the manufacturer’s protocol.
Fig. 1  Identification of protein–protein binding: to identify proteins 
that bind to full-length MIF, a yeast two-hybrid screen was performed 
using a human fetal brain cDNA library. In this screen HTRA1 was 
identified as a binding partner to MIF. a Interacting proteins from 
Y2H screenings were verified by co-transformation experiments. 
Coding regions of interacting proteins were expressed in pGADT7 
and transformed into Y2HGold expressing pGBKT MIF. Co-trans-
formed Y2HGold were grown on selective agar plates for 3–5  days 
at 30  °C according to the manufacturer’s protocol. The results after 
co-transformation of Y2HGold with pGBKT7-MIF and pGADT7-
candidate prey. DDO is Double Dropout:(SD/-Leu/-Trp) while DDO/
X/A is DDO plus X-α-gal and Aureobasidin-A. QDO is quadruple 
dropout. b Full-length HTRA1 is a 480 amino acid protein contain-
ing an IGF binding region and a serine protease domain, between 
amino acids 204 and 364. In the extreme C-terminus a PDZ domain 
is found. The cDNA clone isolated by us (in the co-transformation) 
contained the coding sequence for the whole PDZ domain and part 
of the protease domain. To determine what part of the MIF molecule 
binds to HTRA1, we made C-terminally truncated constructs of MIF 
(lines). The truncations where made so that that the two α-helix’s 
where intact, since these are facing outwards in the MIF trimer. We 
also used software modeling to predict potential interaction sites on 
MIF and HTRA1 (c, d). Since there is no crystal structure for the 
HTRA1 molecule available containing both the protease domain and 
the PDZ domain, we modeled the two domains separately and both 
are predicted to interact with MIF (pink). The PDZ domain (blue) is 
predicted to interact with the loop between the N-terminal β-sheet 
and the first α-helix (c), while the protease domain (green) interacts 
with the first α-helix (d)
4564 Å. Fex Svenningsen et al.
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Software analysis of the MIF–HTRA1 interaction
To determine hypothetical MIF–HTRA1 binding sites, the 
program Patchdock (Beta 1.3 Version) was used to iden-
tify molecular docking. The protein data bank (PDB) files 
for MIF (1ca7) and HTRA1 (2joa and 3num) were used for 
modeling. The Patchdock results were refined using the Fire-
Dock software [51, 52].
Microscale thermophoresis
Recombinant human HTRA1 (R&D Systems, 2916-SE) was 
labeled using the Monolith NT™Protein Labeling Kit RED-
NHS (NanoTemper Technologies). Labeling was performed 
according to the manufacturers instructions in coupling 
buffer (50 mM HEPES, 700 mM NaCl, pH 8.2), applying a 
concentration of 5.5 µM HTRA1 and a molar dye to protein 
ratio of 5:1. Removal of unreacted dye was performed with 
the supplied columns equilibrated in assay buffer (50 mM 
Tris, 0.05% Tween-20, pH 8.0).
Labeled HTRA1 as well as the unlabeled MIF (Pepro-
Tech, 300-69) were diluted in the assay buffer. The concen-
tration of HTRA1 was kept constant at 65 nM throughout 
the measurements, whereas MIF was titrated in 2:1 dilutions, 
ranging from 2.28 nM to 1 µM. For the measurements, each 
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Fig. 2  Interaction analysis of the MIF–HTRA1 binding: Microscale 
thermophoresis (MST) measurements were performed on the bind-
ing between HTRA1 and MIF. The MST measurements were made 
using a constant concentration of labeled HTRA1 while the concen-
tration of the non-labeled MIF was varied. The MST measurements 
were performed using a Monolith NT.115. A KD of 147  ±  16  nM 
was determined for this interaction employing the Thermophore-
sis  +  T-Jump signal for data analysis (n  =  3 independent measure-
ments, error bars represent the standard deviation)
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Fig. 3  Functional analysis of the MIF–HTRA1 binding: the func-
tion of the MIF and HTRA1 binding was first tested with β-casein, a 
known substrate for HTRA1 (a). The addition of HTRA1 effectively 
cleaved the β-casein. A new sample was then mixed, adding β-casein 
together with HTRA1 and MIF. Interestingly, MIF effectively inhib-
ited the HTRA1-mediated cleaving of β-casein. It is known that 
FGF8 is also cleaved by HTRA1. Therefore, the experiment was 
repeated with FGF8 instead of β-casein. HTRA1 cleaved FGF8 as 
previously described, but the addition of MIF effectively inhibited 
the cleavage (b). FGF18, which is closely related to FGF8, was also 
effectively cleaved by HTRA1 and the cleavage was significantly 
inhibited by MIF (c). The coomassie gel for each experiment is added 
below the diagram. Error bars represent SEM, n  =  3. *p   <   0.05, 
**p  <  0.01, ***p < 0.001
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Fig. 4  Immunochemical investigation of protein expression: The 
presence of MIF (a), HTRA1 (b), FGF8 (c) and FGF18 (d) were 
investigated in cultured mouse astrocytes co-labeled with GFAP. 
It was found that the astrocytes express MIF as well as HTRA1 in 
their cytoplasm. The somewhat grainy labeling of MIF may indicate 
that the protein is stored in vesicles in the cytoplasm. HTRA1 is also 
localized to the cytoplasm, as are FGF8 and FGF18. DAPI was used 
for nuclear staining. Error bars are 50 µm
4566 Å. Fex Svenningsen et al.
1 3
MIF dilution was incubated with labeled HTRA1 for 20 min 
at RT before being loaded into hydrophilic glass capillaries 
(NanoTemper Technologies). Measurements were performed 
using a Monolith NT.115 instrument (NanoTemper Technol-
ogies) at an ambient temperature of 25 °C with 5 s/30 s/5 s 
laser off/on/off times, respectively. Instrument parameters 
were adjusted to 40% LED power and 80% MST power. 
Data from three independently pipetted experiments were 
analyzed using the signal from Thermophoresis + T-jump.
Animals
C57BL/6J mice were purchased from Taconic (Denmark). 
The mice were kept on a 12-h dark–light cycle with food and 
water ad libitum. The study was approved by the regional 
ethics committee for research animals (Odense, Denmark). 
The mice pups (P1–P5) were decapitated using sharp 
scissors.
Isolation of primary astrocytes
For experiments involving astrocytes, brains of P1–P5 
mice were mechanically dissociated and the obtained 
cells cultivated in DMEM supplemented with 10% fetal 
bovine serum and penicillin–streptomycin for a minimum 
of 10 days. The protocol of de Vellis and Cole was fol-
lowed for purification of astrocytes [53]. In short, the 
flasks containing mixed glial cultures were placed on a 
rotary shaker at 37 °C, 200 rpm, first for 4 h to remove 
microglia. The medium with microglia was discarded, and 
new medium was added and the flasks shaken for addi-
tional 12–18 h under same conditions. The medium was 
then collected and centrifuged at 1000 rpm, The flasks 
were washed with pre- warmed medium once and then 
medium containing Dulbecco’s Modified Eagle Medium 
(DMEM) with glutamax containing 10% fetal bovine 
serum (FBS) and 1× penicillin and streptomycin (Gibco) 
was added to the astrocytes that adhered to the bottom. 
Purified astrocytes were removed using trypsin and re-
plated in Permanox 4 well Chamber slides (Gibco) for 
further processing.
Transfection of HEK 293 cells with HTRA1
Full-length HTRA1 was cloned into the pcDNA3 mam-
malian expression vector kindly provided by Prof. Alfonso 
Baldi. HEK293 cells at a confluence of 70% were transfected 
with the plasmid using lipofectamine LTX transfection rea-
gent (Invitrogen). Stable transfection was ensured by the 
addition of 500 µg/mL geneticin to the culture medium for 
several weeks.
For assays using medium of HTRA1-transfected HEK293 
cells, the cells were grown until reaching a confluence of 
approximately 90%. The medium was changed to serum-
free DMEM in a volume just covering the surface of the 
flask. The cultures were then incubated for 26–30 h, and the 
enriched medium collected, centrifuged at 1200 rpm, 5 min, 
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Fig. 5  In vitro functional analysis using cultured mouse astrocytes: 
MIF blocks HTRA1-mediated inhibition of FGF8-stimulated astro-
cyte migration (a). Using the scratch assay, astrocyte migration was 
enhanced using FGF8. When HTRA1 was added in combination with 
FGF8, the migration decreased significantly. In cultures where FGF8, 
HTRA1 and MIF were added together, astrocyte migration signifi-
cantly increased to a level similar to that of cultures that only received 
FGF8, n = 5. HTRA1 or MIF in combination or alone added to astro-
cyte cultures did not have any effect on migration in the cultures 
(b), n  =  3. The same experiment was also made with FGF18, with 
the same result. Error bars represent SEM. *p  <  0.05, **p  <  0.01, 
***p < 0.001
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and used for cleavage and proliferation assays. Medium 
from untransfected cell was used as a control. For all pre-
sented cleavage assays, the aliquots from the same collected 
batch of medium were used to ensure a constant amount of 
HTRA1.
Activity assay
For the activity assay with HTRA1, substrates were used in 
different concentrations. β-casein (1 µg) was used as positive 
control, while FGF8, 0.5 µg (Pepro-Tech, 100-25), and both 
FGF17 (Pepro-Tech, 100-27) and FGF18 (Pepro-Tech, 100-
28) were investigated as possible substrates using 0.75 µg 
in the assay.
To obtain active HTRA1, medium was collected from 
the transfected HEK293 cells. The amount of HTRA1-con-
taining medium optimal for cleavage was first investigated 
as the lowest concentration cleaving 1 µg β-casein. Through 
testing, the lowest amount leading to visible cleavage of the 
substrate was found to be 4 µL, this amount was used for 
further analysis; medium from untransfected HEK cells was 
used as control (see Supplementary figure 1). To determine 
the actual concentration of the HTRA1 from the medium, 
western blots were made with the media containing HTRA1 
and several concentrations of recombinant HTRA1 (R&D 
systems (R&D Systems, 2916-SE) 1–200 ng. The concentra-
tion of HTRA1 in the media was determined to be between 
10 and 50 ng/µL.
Medium from untransfected HEK293 cells served as 
control and was used in the same amounts as the HTRA1 
containing medium (see Supplementary figure  1). The 
samples were prepared in a total volume of 20 µL in assay 
buffer (50 mM Tris–HCl, pH 8.0). For the examination 
of MIF’s inhibitory effect on HTRA1, MIF (Pepro-Tech, 
300-69) ranging from 0.001–5 µg was added to the lowest 
volume of HTRA1 cleaving β-casein, in a total volume of 
20 µL in assay buffer. These proteins were incubated for 
10 min before addition of 1 µg of β-casein to the samples. 
The samples were incubated for 2 h at 37 °C. The lowest 
concentration of MIF able to inhibit the enzymatic activity 
of HTRA1 was determined to be 1 µg and this was used for 
further activity studies with β-casein (see Supplementary 
figure 1C).
When using FGF8 and FGF18 as substrates, 12.5 µL of 
HTRA1-containing medium and correspondingly 3 µg MIF 
were used. For FGF17 and FGF18 samples were incubated 
overnight at 37 °C (see Supplementary figure 1).
After incubation, the samples were separated on a 15% 
SDS polyacrylamide gel and stained using SimplyBlue™ 
SafeStain (Invitrogen) according to the manufacture’s pro-
tocol. Destaining was performed overnight in  ddH2O sup-
plemented with 20% NaCl.
Analysis of astrocyte migration
To investigate migration a protocol for the scratch test/
wound healing was used [54, 55]. In short, Permanox 4 well 
Chamber slides (Gibco), were used for the procedure. In 
the bottom of the slides, five vertical reference lines were 
made with a scalpel. Primary astrocytes, 60,000 cells/mL 
were then seeded into the poly-D lysine coated dishes. 
The cells were grown for 24 h—16 of these in FBS-free 
medium to inhibit cell proliferation during the assay until 
80% confluent. A horizontal scratch was made with a 10-µL 
pipette tip, and the medium was carefully changed to pre-
warmed DMEM [56, 57]. Pictures were taken at t0, and 
the test substances were added. These included 25 ng/mL 
FGF8, collected HTRA1-containing medium in the ratio to 
FGF8 determined in the activity assay (0.12 µL), and 50 ng/
mL MIF. In assays where MIF and HTRA1 were added in 
combination with the cells, they were pre-incubated for at 
least 5 min before the addition. After addition of the test 
substances, the cells were incubated for an additional 24 h. 
Pictures taken after this time were designated t24. The pic-
tures were taken at the intersections of each reference line 
with the scratch, thereby ten pictures were taken from each 
well and it was ensured that t0 and t24 were captured at the 
same positions within the wells.
Immunocytochemistry
The cells were fixed in 4% PFA for 10 min and washed 
three times in washing buffer. After washing three times in 
washing buffer (PBS + 0.25% Triton X-100 + 025% BSA), 
the slides containing astrocytes were blocked in blocking 
solution (PBS + 0.25% Triton X-100) for 30 min at room 
temperature. Incubation with the corresponding antibodies 
diluted in blocking solution was done overnight at 4 °C. The 
following primary antibodies were used: primary polyclonal 
rabbit anti-MIF antibody (1:200; Abcam ab7207), primary 
polyclonal rabbit HTRA1 (1:200, A kind gift from Michael 
Ehrmann at Universität Duisburg-Essen, Essen, Germany), 
primary polyclonal chicken anti-GFAP (1:1.000; Abcam, 
ab4674), polyclonal rabbit anti-FGF8 (1:200, Abcam, 
ab81384) and polyclonal mouse anti-FGF18 (1:200, Abcam, 
ab169615). Incubation with the secondary antibodies was 
performed in the dark at room temperature for 1 h. The sec-
ondary antibodies were as following: Alexa Fluor-488 goat 
anti-rabbit IgG (1:400; Invitrogen, 828814), Rhodamine 
Red-X goat anti-chicken (1:400; Jackson Immuno Research, 
93951) and Rhodamine Red-X goat anti-mouse (1:400; Jack-
son Immuno Research, 94085). The slides were washed in 
PBS and stained with DAPI for 20 min before mounting. 
For all staining procedures, negative control antibodies were 
performed.
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Statistics
For the analysis of band intensities, pictures were taken and 
analyzed using the program MultiGauge (Fujifilm) and the 
Quick Guide for Quantitative Analysis [Quant (Fujifilm)]. 
The (Q-B)/pixel2 values of bands were standardized to the 
corresponding control sample. The data were compared 
statistically using one-way ANOVA in combination with 
the Bonferroni’s correction with a significance threshold at 
p < 0.05.
The scratch area (area without cells) was calculated for 
each picture using ImageJ. The t24 value was subtracted from 
the corresponding t0 value, and designated as the reduction 
in scratch area given in  mm2. An average was calculated 
from all ten pictures of each well (10–18 wells per condi-
tion, 6 different experiments). With the program GraphPad 
Grubb’s test, the values were analyzed for outliers, which 
were then removed manually. Statistical analysis was done 
using the GraphPad and one-way ANOVA in combination 
with the Bonferroni’s correction with a significance thresh-
old at p < 0.05. BrdU was added during the 24 h. The cul-
tures were fixed and treated as described below. Immuno-
cytochemistry of the cultures was performed using BrdU, 
to investigate proliferation. This investigation showed no 
significant difference between control and treated cells (data 
not shown).
Results
Finding new binding partners to MIF
An yeast two-hybrid screen was performed using a human 
fetal brain cDNA library to identify proteins that bind to full-
length MIF. Here we identified a new interacting protein: a 
member of the trypsin family of serine proteases, HTRA1. 
The cDNA clone isolated contained the coding sequence 
for the C-terminal 193 amino acids of HTRA1. Full-length 
HTRA1 contains 480 amino acids and the serine protease 
domain is found between amino acids 204 and 364. In the 
extreme C-terminus, following the protease domain, a PDZ 
domain is found. The cDNA clone we isolated therefore con-
tained the coding sequence for the whole PDZ domain and 
part of the protease domain (Fig. 1a). The cDNA clone also 
contained non-coding sequences. To confirm that it was the 
HTRA1 coding sequences that resulted in a positive interac-
tion in the yeast two-hybrid screen, all non-coding sequences 
were removed and the interaction was confirmed by direct 
mating in yeast.
To determine which part of the MIF molecule that is 
involved in the interaction with HTRA1, we made C-termi-
nally truncated constructs of MIF (Fig. 1a). The truncations 
were made in a way that the two α-helixes were intact, since 
these are facing outwards in the MIF trimer. These truncated 
constructs were then used for direct mating experiments in 
yeast, showing that the first 38 amino acids of MIF, that con-
tain the first α-helix, bind to HTRA1. We then made trun-
cated HTRA1 constructs containing either the PDZ domain 
or the part of the protease domain that was pulled out of the 
cDNA library. When these constructs were used for direct 
mating experiments, no interaction was found. As this was 
an unexpected result, we used software modeling (Patch-
dock and FireDock) to investigate potential binding sites. 
Since there is no crystal structure for the HTRA1 molecule 
available containing both the protease domain and the PDZ 
domain, we modeled the two domains separately. The results 
suggest that both domains interact with MIF (Fig. 1b, c). The 
PDZ domain is predicted to interact with the loop between 
the N-terminal β-sheet and the first α-helix (Fig. 1b), while 
the protease domain interacts with the first α-helix (Fig. 1c). 
The modeling results are in agreement with the results from 
the yeast two-hybrid studies and suggest that both HTRA1 
domains are needed to form a stable interaction with MIF.
Verification of the binding between MIF and HTRA1
The binding between MIF and HTRA1 was further verified 
using microscale thermophoresis (MST). The measurements 
were performed using a constant concentration of labeled 
HTRA1 (65 nM) while the concentration of the non-labeled 
MIF, varied between 2.2 nM–1 μM. A KD of 147 ± 16 nM 
(n = 3) was determined for the interaction (Fig. 2). This KD 
is in the physiological range and the binding is thus likely to 
occur in tissues such as the nervous system [58].
MIF inhibits the enzymatic digestion mediated 
by HTRA1
We next tested the function of the MIF–HTRA1 interaction. 
HTRA1 has been reported to cleave β-casein [13] and we 
therefore replicated this in our experiments. Interestingly, the 
addition of MIF to HTRA1 before the addition of β-casein, 
inhibited the HTRA1-mediated enzymatic breakdown sig-
nificantly (Fig. 3a). HTRA1 is also known to enzymatically 
digest fibroblast growth factor-8 (FGF8) [13]. Next, we 
investigated if MIF had the ability to inhibit the enzymatic 
digestion of this protein as well, and this was indeed the case 
(Fig. 3b). There are two other members of the FGF fam-
ily, FGF17 and FGF18 that share a high sequence homol-
ogy with FGF8 [2]. We tested if HTRA1 had the ability to 
enzymatically break down these proteins. It was found that 
HTRA1 could enzymatically digest FGF18, but not FGF17 
and that MIF could inhibit the enzymatic breakdown of this 
protein too (Fig. 3c).
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MIF and HTRA1 expression in vitro
The distribution of MIF in the CNS has previously been 
studied and MIF is present in most cells of the CNS [12, 
59–61]. However, the distribution of HTRA1 in the CNS is 
relatively unknown although, as mentioned previously, it has 
been found in both neurons as well as glia [33, 36]. We have 
previously found that MIF is highly expressed in astrocytes 
[62] and that this cell type express HTRA1 as well. Unfortu-
nately, we could not obtain data of complete co-localization 
since the working antibodies are both made within the rab-
bit immune system. As shown in Fig. 4, astrocytes labeled 
with GFAP express both MIF and HTRA1 (Fig. 4a, b), and 
the proteins have a similar distribution. Since HTRA1 enzy-
matically digests both FGF8 and FGF18, we also chose to 
determine if these proteins were present in astrocytes. It was 
found that astrocytes do express FGF8 as well as FGF18 
(Fig. 4c, d).
HTRA1 decreases FGF8‑induced astrocyte migration, 
while MIF inhibits this HTRA1‑mediated effect
Since both MIF and HTRA1 are present in astrocytes, we 
went on to study the function of the MIF–HTRA1 interac-
tion in this cell type. It has previously been shown that FGF8 
influences the migration, but not proliferation of astrocytes 
in vitro using a scratch/wound healing assay [43, 54, 63]. 
Since FGF8 mediates increased migration, we reasoned 
that this effect could be inhibited by HTRA1. Replicating 
Kang et al. [43], astrocyte migration was first investigated 
with and without FGF8. In cultures where FGF8 was added, 
astrocytes migration was significantly increased compared 
to control cultures (Fig. 5a), whereas cell proliferation was 
not affected (data not shown). When HTRA1 was added in 
combination with FGF8, the migration decreased signifi-
cantly (Fig. 5a). In fact, the migration in these cultures was 
similar to the migration levels in the control cultures. In 
cultures where FGF8, HTRA1 and MIF were added together, 
astrocyte migration significantly increased to a level similar 
to that of cultures that only received FGF8 (Fig. 5a). HTRA1 
or MIF in combination or alone, added to astrocyte cultures, 
did not have any effect on migration in the cultures (Fig. 5b).
Discussion
MIF is highly expressed throughout the central nervous sys-
tem (CNS) and identified in most cells in nervous tissue 
including neurons, ependymal cells, astrocytes, oligoden-
drocytes, neural stem cells/progenitor cells, activated micro-
glia, and Schwann cells [59, 62, 64, 65]. Several previous 
investigations have suggested that MIF may be involved in 
nervous system development, though the function of MIF in 
this setting is far from clear, and receptor as well as binding 
partner distributions are unknown [4, 12, 66]. To delineate 
this, we searched for new MIF binding partners in the CNS 
using a human fetal brain cDNA library and found HTRA1, 
an enzyme that belongs to a family of four members (the ser-
ine proteases 1–4). These family members share a relatively 
high sequence homology, but differ in cellular functions 
[32]. The primary structure of the protein consists of five 
different parts: signal peptide (SP), insulin-like growth fac-
tor-binding domain (IGF-BP), Kazal inhibitor (KI), protease, 
and PDZ domain. In the case of the MIF–HTRA1 binding, 
we found that MIF likely binds to both the PDZ domain and 
the protease domain. The yeast hybrid and protein modeling 
results (Fig. 1b, c) also suggest that stability in this binding 
is only accomplished by binding to both domains.
Several proteolytic substrates for HTRA1 have been iden-
tified, as for example insulin-like growth factor-binding pro-
tein 5 (IGF-BP-5), fibroblast growth factor-8 (FGF8), trans-
forming growth factor β (TGF- β) as well as extracellular 
matrix components such as aggrecan, decorin, fibromodulin 
and soluble type II collagen [13, 35, 36, 40, 42, 67].
Since HTRA1 enzymatically digest FGF8 [13], we tested 
if MIF binding to HTRA1 would inhibit this enzymatic 
breakdown. Interestingly, this was the case. We also tested 
if HTRA1 would break down the close relatives to FGF8, 
FGF17 and FGF18. Surprisingly, we found that HTRA1 
digested FGF18, but not FGF17, although the breakdown 
of FGF18 needed a higher concentration of HTRA1 and 
a longer incubation period than for FGF8. MIF, in turn, 
also had the ability to inhibit the breakdown of both FGF8 
and FGF18. Since both MIF and HTRA1 expression are 
common in most tissues, we suggest that the inhibition of 
HTRA1-mediated enzymatic breakdown by MIF is com-
monly occurring in tissues where both proteins are present. 
No endogenous proteins that have the ability to regulate 
HTRA1’s protease function have been found previously [68]. 
Thus, MIF is the first to do so.
As stated previously, both MIF and HTRA1 are present 
in most cells of the CNS. We found that astrocytes express 
MIF and HTRA1 as well as FGF8 and FGF18. Young astro-
cytes have a relatively higher immunoreactivity for all of the 
proteins mentioned (data not shown). This is also in accord 
with previous findings showing that HTRA1, FGF8 as well 
as FGF18 are implicated in brain development [36, 69, 70].
To investigate the function of the MIF–HTRA1 binding, 
we used cultured mouse astrocytes. It has previously been 
shown that FGF8 increases migration, but not proliferation 
in such cells [43]. We investigated if HTRA1 would inhibit 
this migration and indeed this was the case. Adding FGF8, 
HTRA1 and MIF together to the cells, the migration was 
restored. Neither MIF nor HTRA1 affect astrocyte migration 
on its own. MIF is stored in intracellular pools, and several 
hormonal, mitogenic, and pro-inflammatory stimuli can 
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elicit its secretion [71]. Although several secretion-stimulat-
ing factors such as glucocorticoids, INFγ, LPS and hypoxia 
have been identified, the exact mechanism of secretion is not 
known [72, 73]. Both HTRA1 and FGF8 are secreted from 
cells during development and in adult organisms [42, 74]. 
Since astrocytes express all three proteins, it is conceivable 
that MIF and HTRA1 interact during certain conditions in 
the CNS. Our data suggest that MIF may aid regeneration 
after CNS injury, by inhibiting HTRA1 that is continuously 
secreted from cells. An increase of MIF thus contributes to 
the increase of growth factors, such as FGF8, FGF18 and 
TGF-β that in turn can increase astrocyte and oligodendro-
cyte migration and proliferation as well as neural protection 
[75–77].
Acknowledgements We would like to thank Karen Rich, Randi God-
skesen and Helle Vinsløv Jensen for expert technical assistance, Jamie 
Stevens for editing our English. Prof. Dr Michael Ehrmann for the 
HTRA1 antibody. The project was supported by the Swedish Research 
Council; Grant number: M 2006-4268, Åhlen-stiftelsen, A. P. Møller, 
Hustru Chastine Mc-Kinney Møllers Fond til Almene Formaal, Jascha-
fonden and Lundbeckfonden, Grant number: R54-A5415.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to 
the Creative Commons license, and indicate if changes were made.
References
 1. Bhasin M, Wu M, Tsirka SE (2007) Modulation of microglial/
macrophage activation by macrophage inhibitory factor (TKP) 
or tuftsin (TKPR) attenuates the disease course of experi-
mental autoimmune encephalomyelitis. BMC Immunol 8:10. 
doi:10.1186/1471-2172-8-10
 2. Ito K, Yoshiura Y, Ototake M, Nakanishi T (2008) Macrophage 
migration inhibitory factor (MIF) is essential for development 
of zebrafish, Danio rerio. Dev Comp Immunol 32(6):664–672. 
doi:10.1016/j.dci.2007.10.007
 3. Odemis V, Boosmann K, Heinen A, Kury P, Engele J (2010) 
CXCR7 is an active component of SDF-1 signalling in astrocytes 
and Schwann cells. J Cell Sci 123(Pt 7):1081–1088. doi:10.1242/
jcs.062810
 4. Conboy L, Varea E, Castro JE, Sakouhi-Ouertatani H, Calandra 
T, Lashuel HA, Sandi C (2011) Macrophage migration inhibi-
tory factor is critically involved in basal and fluoxetine-stimulated 
adult hippocampal cell proliferation and in anxiety, depression, 
and memory-related behaviors. Mol Psychiatry 16(5):533–547. 
doi:10.1038/mp.2010.15
 5. Ohta S, Misawa A, Fukaya R, Inoue S, Kanemura Y, Okano H, 
Kawakami Y, Toda M (2012) Macrophage migration inhibi-
tory factor (MIF) promotes cell survival and proliferation of 
neural stem/progenitor cells. J Cell Sci 125(Pt 13):3210–3220. 
doi:10.1242/jcs.102210
 6. Zhang X, Chen L, Wang Y, Ding Y, Peng Z, Duan L, Ju G, Ren 
Y, Wang X (2013) Macrophage migration inhibitory factor pro-
motes proliferation and neuronal differentiation of neural stem/
precursor cells through Wnt/beta-catenin signal pathway. Int J 
Biol Sci 9(10):1108–1120. doi:10.7150/ijbs.7232
 7. Williams JL, Patel JR, Daniels BP, Klein RS (2014) Targeting 
CXCR7/ACKR3 as a therapeutic strategy to promote remyelina-
tion in the adult central nervous system. J Exp Med 211(5):791–
799. doi:10.1084/jem.20131224
 8. Fingerle-Rowson GR, Bucala R (2001) Neuroendocrine properties 
of macrophage migration inhibitory factor (MIF). Immunol Cell 
Biol 79(4):368–375. doi:10.1046/j.1440-1711.2001.01024.x
 9. Waeber G, Calandra T, Roduit R, Haefliger JA, Bonny C, 
Thompson N, Thorens B, Temler E, Meinhardt A, Bacher M, 
Metz CN, Nicod P, Bucala R (1997) Insulin secretion is regu-
lated by the glucose-dependent production of islet beta cell mac-
rophage migration inhibitory factor. Proc Natl Acad Sci USA 
94(9):4782–4787
 10. Vujicic M, Senerovic L, Nikolic I, Saksida T, Stosic-Grujicic 
S, Stojanovic I (2014) The critical role of macrophage migra-
tion inhibitory factor in insulin activity. Cytokine 69(1):39–46. 
doi:10.1016/j.cyto.2014.05.013
 11. Bank LM, Bianchi LM, Ebisu F, Lerman-Sinkoff D, Smiley EC, 
Shen YC, Ramamurthy P, Thompson DL, Roth TM, Beck CR, 
Flynn M, Teller RS, Feng L, Llewellyn GN, Holmes B, Sharples 
C, Coutinho-Budd J, Linn SA, Chervenak AP, Dolan DF, Benson 
J, Kanicki A, Martin CA, Altschuler R, Koch AE, Jewett EM, 
Germiller JA, Barald KF (2012) Macrophage migration inhibitory 
factor acts as a neurotrophin in the developing inner ear. Develop-
ment 139(24):4666–4674. doi:10.1242/dev.066647
 12. Zhang W, Li L, Wang J, An L, Hu X, Xie J, Yan R, Chen S, Zhao 
S (2014) Expression of macrophage migration inhibitory factor 
in the mouse neocortex and posterior piriform cortices during 
postnatal development. Cell Mol Neurobiol 34(8):1183–1197. 
doi:10.1007/s10571-014-0094-1
 13. Kim GY, Kim HY, Kim HT, Moon JM, Kim CH, Kang S, Rhim H 
(2012) HtrA1 is a novel antagonist controlling fibroblast growth 
factor (FGF) signaling via cleavage of FGF8. Mol Cell Biol 
32(21):4482–4492. doi:10.1128/MCB.00872-12
 14. Nishio Y, Nishihira J, Ishibashi T, Kato H, Minami A (2002) 
Role of macrophage migration inhibitory factor (MIF) in periph-
eral nerve regeneration: anti-MIF antibody induces delay of 
nerve regeneration and the apoptosis of Schwann cells. Mol Med 
8(9):509–520
 15. Yang Y, Xie Y, Chai H, Fan M, Liu S, Liu H, Bruce I, Wu W 
(2006) Microarray analysis of gene expression patterns in adult 
spinal motoneurons after different types of axonal injuries. Brain 
Res 1075(1):1–12. doi:10.1016/j.brainres.2005.12.060
 16. Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J (2000) 
Macrophage migration inhibitory factor in the cerebrospi-
nal fluid of patients with conventional and optic-spinal forms 
of multiple sclerosis and neuro-Behcet’s disease. J Neurol Sci 
179(S1–2):127–131
 17. Nishihira J, Ogata A (2001) Macrophage migration inhibitory fac-
tor as a target molecule in multiple sclerosis. Curr Opin Investig 
Drugs 2(6):778–782
 18. Popp J, Bacher M, Kolsch H, Noelker C, Deuster O, Dodel R, 
Jessen F (2009) Macrophage migration inhibitory factor in mild 
cognitive impairment and Alzheimer’s disease. J Psychiatr Res 
43(8):749–753. doi:10.1016/j.jpsychires.2008.10.006
 19. Akcali A, Pehlivan S, Pehlivan M, Sever T, Neyal M (2010) Asso-
ciation of macrophage migration inhibitory factor gene promoter 
polymorphisms with multiple sclerosis in Turkish patients. J Int 
Med Res 38(1):69–77
 20. Nicoletti A, Fagone P, Donzuso G, Mangano K, Dibilio V, 
Caponnetto S, Bendtzen K, Zappia M, Nicoletti F (2011) Parkin-
son’s disease is associated with increased serum levels of mac-
rophage migration inhibitory factor. Cytokine 55(2):165–167. 
doi:10.1016/j.cyto.2011.03.027
4571Macrophage migration inhibitory factor (MIF) modulates trophic signaling through interaction…
1 3
 21. Oyama R, Yamamoto H, Titani K (2000) Glutamine synthetase, 
hemoglobin alpha-chain, and macrophage migration inhibitory 
factor binding to amyloid beta-protein: their identification in 
rat brain by a novel affinity chromatography and in Alzheimer’s 
disease brain by immunoprecipitation. Biochim Biophys Acta 
1479(1–2):91–102
 22. Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, 
Popp J, Noelker C, Reese JP, Al-Abed Y, Dodel R (2010) The role 
of macrophage migration inhibitory factor in Alzheimer’s disease. 
Mol Med 16(3–4):116–121. doi:10.2119/molmed.2009.00123
 23. Bryan KJ, Zhu X, Harris PL, Perry G, Castellani RJ, Smith MA, 
Casadesus G (2008) Expression of CD74 is increased in neu-
rofibrillary tangles in Alzheimer’s disease. Mol Neurodegener 
3:13. doi:10.1186/1750-1326-3-13
 24. Rinta S, Kuusisto H, Raunio M, Paalavuo R, Levula M, Lehti-
maki T, Elovaara I (2008) Apoptosis-related molecules in blood 
in multiple sclerosis. J Neuroimmunol 205(1–2):135–141. 
doi:10.1016/j.jneuroim.2008.09.002
 25. Hagman S, Raunio M, Rossi M, Dastidar P, Elovaara I (2011) 
Disease-associated inflammatory biomarker profiles in blood 
in different subtypes of multiple sclerosis: prospective clinical 
and MRI follow-up study. J Neuroimmunol 234(1–2):141–147. 
doi:10.1016/j.jneuroim.2011.02.009
 26. Kithcart AP, Cox GM, Sielecki T, Short A, Pruitt J, Papenfuss 
T, Shawler T, Gienapp I, Satoskar AR, Whitacre CC (2010) 
A small-molecule inhibitor of macrophage migration inhibi-
tory factor for the treatment of inflammatory disease. FASEB J 
24(11):4459–4466. doi:10.1096/fj.10-162347
 27. Cox GM, Kithcart AP, Pitt D, Guan Z, Alexander J, Williams 
JL, Shawler T, Dagia NM, Popovich PG, Satoskar AR, Whita-
cre CC (2013) Macrophage migration inhibitory factor poten-
tiates autoimmune-mediated neuroinflammation. J Immunol 
191(3):1043–1054. doi:10.4049/jimmunol.1200485
 28. Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows 
GG, Bourdette D, Offner H, Bucala R, Vandenbark AA (2013) 
Partial MHC class II constructs inhibit MIF/CD74 binding 
and downstream effects. Eur J Immunol 43(5):1309–1321. 
doi:10.1002/eji.201243162
 29. Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, 
Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Van-
denbark AA (2014) HLA-DRalpha1 constructs block CD74 
expression and MIF effects in experimental autoimmune 
encephalomyelitis. J Immunol 192(9):4164–4173. doi:10.4049/
jimmunol.1303118
 30. Zumbrunn J, Trueb B (1996) Primary structure of a putative 
serine protease specific for IGF-binding proteins. FEBS Lett 
398(2–3):187–192
 31. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM 
(1998) Human HtrA, an evolutionarily conserved serine protease 
identified as a differentially expressed gene product in osteoar-
thritic cartilage. J Biol Chem 273(51):34406–34412
 32. Nie GY, Hampton A, Li Y, Findlay JK, Salamonsen LA (2003) 
Identification and cloning of two isoforms of human high-tem-
perature requirement factor A3 (HtrA3), characterization of its 
genomic structure and comparison of its tissue distribution with 
HtrA1 and HtrA2. Biochem J 371(Pt 1):39–48. doi:10.1042/
BJ20021569
 33. De Luca A, De Falco M, Severino A, Campioni M, Santini D, 
Baldi F, Paggi MG, Baldi A (2003) Distribution of the serine 
protease HtrA1 in normal human tissues. J Histochem Cytochem 
51(10):1279–1284. doi:10.1177/002215540305101004
 34. De Luca A, De Falco M, De Luca L, Penta R, Shridhar V, Baldi 
F, Campioni M, Paggi MG, Baldi A (2004) Pattern of expression 
of HtrA1 during mouse development. J Histochem Cytochem 
52(12):1609–1617. doi:10.1369/jhc.4A6330.2004
 35. Oka C, Tsujimoto R, Kajikawa M, Koshiba-Takeuchi K, Ina J, 
Yano M, Tsuchiya A, Ueta Y, Soma A, Kanda H, Matsumoto 
M, Kawaichi M (2004) HtrA1 serine protease inhibits signaling 
mediated by Tgfbeta family proteins. Development 131(5):1041–
1053. doi:10.1242/dev.00999
 36. Launay S, Maubert E, Lebeurrier N, Tennstaedt A, Campioni 
M, Docagne F, Gabriel C, Dauphinot L, Potier MC, Ehrmann 
M, Baldi A, Vivien D (2008) HtrA1-dependent proteolysis of 
TGF-beta controls both neuronal maturation and developmen-
tal survival. Cell Death Differ 15(9):1408–1416. doi:10.1038/
cdd.2008.82
 37. Clawson GA, Bui V, Xin P, Wang N, Pan W (2008) Intracel-
lular localization of the tumor suppressor HtrA1/Prss11 and its 
association with HPV16 E6 and E7 proteins. J Cell Biochem 
105(1):81–88. doi:10.1002/jcb.21804
 38. Hansen G, Hilgenfeld R (2013) Architecture and regulation of 
HtrA-family proteins involved in protein quality control and 
stress response. Cell Mol Life Sci 70(5):761–775. doi:10.1007/
s00018-012-1076-4
 39. Tsuchiya A, Yano M, Tocharus J, Kojima H, Fukumoto M, 
Kawaichi M, Oka C (2005) Expression of mouse HtrA1 serine 
protease in normal bone and cartilage and its upregulation in joint 
cartilage damaged by experimental arthritis. Bone 37(3):323–336. 
doi:10.1016/j.bone.2005.03.015
 40. Hou J, Clemmons DR, Smeekens S (2005) Expression and char-
acterization of a serine protease that preferentially cleaves insulin-
like growth factor binding protein-5. J Cell Biochem 94(3):470–
484. doi:10.1002/jcb.20328
 41. Grau S, Richards PJ, Kerr B, Hughes C, Caterson B, Williams 
AS, Junker U, Jones SA, Clausen T, Ehrmann M (2006) The role 
of human HtrA1 in arthritic disease. J Biol Chem 281(10):6124–
6129. doi:10.1074/jbc.M500361200
 42. An E, Sen S, Park SK, Gordish-Dressman H, Hathout Y (2010) 
Identification of novel substrates for the serine protease HTRA1 
in the human RPE secretome. Invest Ophthalmol Vis Sci 
51(7):3379–3386. doi:10.1167/iovs.09-4853
 43. Kang K, Lee SW, Han JE, Choi JW, Song MR (2014) The com-
plex morphology of reactive astrocytes controlled by fibroblast 
growth factor signaling. Glia 62(8):1328–1344. doi:10.1002/
glia.22684
 44. Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, 
Catricala C, Amantea A, Noonan DM, Albini A, Natali PG, Lom-
bardi D, Paggi MG (2002) The HtrA1 serine protease is down-
regulated during human melanoma progression and represses 
growth of metastatic melanoma cells. Oncogene 21(43):6684–
6688. doi:10.1038/sj.onc.1205911
 45. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ, Chen 
H, Zhao Y, Pearson E, Li X, Chien J, Dewan A, Harmon J, Bern-
stein PS, Shridhar V, Zabriskie NA, Hoh J, Howes K, Zhang K 
(2006) A variant of the HTRA1 gene increases susceptibility to 
age-related macular degeneration. Science 314(5801):992–993. 
doi:10.1126/science.1133811
 46. Hou Y, Lin H, Zhu L, Liu Z, Hu F, Shi J, Yang T, Shi X, Guo 
H, Tan X, Zhang L, Wang Q, Li Z, Zhao Y (2014) The inhibi-
tory effect of IFN-gamma on protease HTRA1 expression in 
rheumatoid arthritis. J Immunol 193(1):130–138. doi:10.4049/
jimmunol.1302700
 47. Beaufort N, Scharrer E, Kremmer E, Lux V, Ehrmann M, Huber 
R, Houlden H, Werring D, Haffner C, Dichgans M (2014) Cer-
ebral small vessel disease-related protease HtrA1 processes latent 
TGF-beta binding protein 1 and facilitates TGF-beta signaling. 
Proc Natl Acad Sci USA 111(46):16496–16501. doi:10.1073/
pnas.1418087111
 48. Cai B, Zeng J, Lin Y, Lin Y, Lin W, Lin W, Li Z, Wang N (2015) 
A frameshift mutation in HTRA1 expands CARASIL syndrome 
4572 Å. Fex Svenningsen et al.
1 3
and peripheral small arterial disease to the Chinese population. 
Neurol Sci 36(8):1387–1391. doi:10.1007/s10072-015-2121-5
 49. Nozaki H, Kato T, Nihonmatsu M, Saito Y, Mizuta I, Noda T, 
Koike R, Miyazaki K, Kaito M, Ito S, Makino M, Koyama A, 
Shiga A, Uemura M, Sekine Y, Murakami A, Moritani S, Hara 
K, Yokoseki A, Kuwano R, Endo N, Momotsu T, Yoshida M, 
Nishizawa M, Mizuno T, Onodera O (2016) Distinct molecular 
mechanisms of HTRA1 mutants in manifesting heterozygotes 
with CARASIL. Neurology 86(21):1964–1974. doi:10.1212/
WNL.0000000000002694
 50. Poepsel S, Sprengel A, Sacca B, Kaschani F, Kaiser M, Gatsogi-
annis C, Raunser S, Clausen T, Ehrmann M (2015) Determinants 
of amyloid fibril degradation by the PDZ protease HTRA1. Nat 
Chem Biol 11(11):862–869. doi:10.1038/nchembio.1931
 51. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ 
(2005) PatchDock and SymmDock: servers for rigid and sym-
metric docking. Nucleic Acids Res 33(Web server issue):W363–
W367. doi:10.1093/nar/gki481
 52. Andrusier N, Nussinov R, Wolfson HJ (2007) FireDock: fast inter-
action refinement in molecular docking. Proteins 69(1):139–159. 
doi:10.1002/prot.21495
 53. de Vellis J, Cole R (2012) Preparation of mixed glial cul-
tures from postnatal rat brain. Methods Mol Biol 814:49–59. 
doi:10.1007/978-1-61779-452-0_4
 54. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a 
convenient and inexpensive method for analysis of cell migration 
in vitro. Nat Protoc 2(2):329–333. doi:10.1038/nprot.2007.30
 55. Pluchino LA, Wang HC (2014) Chronic exposure to combined 
carcinogens enhances breast cell carcinogenesis with mesen-
chymal and stem-like cell properties. PLoS One 9(11):e108698. 
doi:10.1371/journal.pone.0108698
 56. Nobes CD, Hall A (1999) Rho GTPases control polarity, pro-
trusion, and adhesion during cell movement. J Cell Biol 
144(6):1235–1244
 57. Holtje M, Hoffmann A, Hofmann F, Mucke C, Grosse G, Van 
Rooijen N, Kettenmann H, Just I, Ahnert-Hilger G (2005) Role 
of Rho GTPase in astrocyte morphology and migratory response 
during in vitro wound healing. J Neurochem 95(5):1237–1248. 
doi:10.1111/j.1471-4159.2005.03443.x
 58. Liu Z, Gong Z, Dong X (1864) Tang C (2016) Transient protein-
protein interactions visualized by solution NMR. Biochim Bio-
phys Acta 1:115–122. doi:10.1016/j.bbapap.2015.04.009
 59. Ogata A, Nishihira J, Suzuki T, Nagashima K, Tashiro K (1998) 
Identification of macrophage migration inhibitory factor mRNA 
expression in neural cells of the rat brain by in situ hybridization. 
Neurosci Lett 246(3):173–177
 60. Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, Metz CN, 
Chesney JA, Gemsa D, Donnelly T, Atkins RC, Bucala R (1998) 
MIF expression in the rat brain: implications for neuronal func-
tion. Mol Med 4(4):217–230
 61. Koda M, Nishio Y, Hashimoto M, Kamada T, Koshizuka S, 
Yoshinaga K, Onodera S, Nishihira J, Moriya H, Yamazaki M 
(2004) Up-regulation of macrophage migration-inhibitory factor 
expression after compression-induced spinal cord injury in rats. 
Acta Neuropathol 108(1):31–36. doi:10.1007/s00401-004-0853-z
 62. Hanrieder J, Wicher G, Bergquist J, Andersson M, Fex-Sven-
ningsen A (2011) MALDI mass spectrometry based molecular 
phenotyping of CNS glial cells for prediction in mammalian brain 
tissue. Anal Bioanal Chem. doi:10.1007/s00216-011-5043-y
 63. Decaestecker C, Debeir O, Van Ham P, Kiss R (2007) Can anti-
migratory drugs be screened in vitro? A review of 2D and 3D 
assays for the quantitative analysis of cell migration. Med Res 
Rev 27(2):149–176. doi:10.1002/med.20078
 64. Nishibori M, Nakaya N, Tahara A, Kawabata M, Mori S, Saeki K 
(1996) Presence of macrophage migration inhibitory factor (MIF) 
in ependyma, astrocytes and neurons in the bovine brain. Neurosci 
Lett 213(3):193–196
 65. Nishio Y, Minami A, Kato H, Kaneda K, Nishihira J (1999) Iden-
tification of macrophage migration inhibitory factor (MIF) in rat 
peripheral nerves: its possible involvement in nerve regeneration. 
Biochim Biophys Acta 1453(1):74–82
 66. Shen YC, Thompson DL, Kuah MK, Wong KL, Wu KL, Linn SA, 
Jewett EM, Shu-Chien AC, Barald KF (2012) The cytokine mac-
rophage migration inhibitory factor (MIF) acts as a neurotrophin 
in the developing inner ear of the zebrafish, Danio rerio. Dev Biol 
363(1):84–94. doi:10.1016/j.ydbio.2011.12.023
 67. Vierkotten S, Muether PS, Fauser S (2011) Overexpression of 
HTRA1 leads to ultrastructural changes in the elastic layer of 
Bruch’s membrane via cleavage of extracellular matrix compo-
nents. PLoS One 6(8):e22959. doi:10.1371/journal.pone.0022959
 68. Eigenbrot C, Ultsch M, Lipari MT, Moran P, Lin SJ, Ganesan 
R, Quan C, Tom J, Sandoval W, van Lookeren Campagne M, 
Kirchhofer D (2012) Structural and functional analysis of HtrA1 
and its subdomains. Structure 20(6):1040–1050. doi:10.1016/j.
str.2012.03.021
 69. Sato T, Joyner AL (2009) The duration of Fgf8 isthmic organizer 
expression is key to patterning different tectal-isthmo-cerebel-
lum structures. Development 136(21):3617–3626. doi:10.1242/
dev.041210
 70. Sunmonu NA, Li K, Li JY (2011) Numerous isoforms of Fgf8 
reflect its multiple roles in the developing brain. J Cell Physiol 
226(7):1722–1726. doi:10.1002/jcp.22587
 71. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, 
Calandra T, Gemsa D, Donnelly T, Atkins RC, Bucala R (1997) 
Migration inhibitory factor expression in experimentally induced 
endotoxemia. Am J Pathol 150(1):235–246
 72. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J 
(2003) Regulated secretion of macrophage migration inhibitory 
factor is mediated by a non-classical pathway involving an ABC 
transporter. FEBS Lett 551(1–3):78–86
 73. Merk M, Baugh J, Zierow S, Leng L, Pal U, Lee SJ, Ebert AD, 
Mizue Y, Trent JO, Mitchell R, Nickel W, Kavathas PB, Bernha-
gen J, Bucala R (2009) The Golgi-associated protein p115 medi-
ates the secretion of macrophage migration inhibitory factor. J 
Immunol 182(11):6896–6906. doi:10.4049/jimmunol.0803710
 74. Lu J, Lu K, Li D (2012) Changes in expression and secretion 
patterns of fibroblast growth factor 8 and Sonic Hedgehog sign-
aling pathway molecules during murine neural stem/progenitor 
cell differentiation in vitro. Neural Regen Res 7(22):1688–1694. 
doi:10.3969/j.issn.1673-5374.2012.22.002
 75. Mark RJ, Fuson KS, Keane-Lazar K, May PC (1999) Fibroblast 
growth factor-8 protects cultured rat hippocampal neurons from 
oxidative insult. Brain Res 830(1):88–93
 76. Huang XQ, Zhang XY, Wang XR, Yu SY, Fang SH, Lu YB, 
Zhang WP, Wei EQ (2012) Transforming growth factor beta1-
induced astrocyte migration is mediated in part by activating 
5-lipoxygenase and cysteinyl leukotriene receptor 1. J Neuroin-
flammation 9:145. doi:10.1186/1742-2094-9-145
 77. Cruz-Martinez P, Martinez-Ferre A, Jaramillo-Merchan J, 
Estirado A, Martinez S, Jones J (2014) FGF8 activates prolif-
eration and migration in mouse post-natal oligodendrocyte 
progenitor cells. PLoS One 9(9):e108241. doi:10.1371/journal.
pone.0108241
